The FDA enforcement report dated 9 September lists a Class II recall by Baxter Healthcare of pantoprazole sodium in 0.9% sodium chloride, 80 mg/100 mL, in GALAXY single-dose infusion bags, for deviation from current good manufacturing practice. It is ongoing, and sits alongside recalls of several other Baxter premixed products on the same date.
No specific defect or patient harm is described. The practical effect is on units using premixed pantoprazole for upper GI bleeding, which will revert to reconstituted vials. That changes preparation, not the regimen. The recall is a US action; Indian availability of this product is not stated.
- Ask pharmacy whether affected lots are stocked in ED, ICU or endoscopy
- Use reconstituted pantoprazole vials as an alternative
- Keep the same dosing regimen after endoscopic haemostasis
Why it matters
Premixed PPI bags are used in high-risk bleeding, where a supply gap should not delay treatment.
Don't overread it
A CGMP recall reflects manufacturing findings, not a safety concern about pantoprazole.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free